Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.

被引：1
|
作者：
Sartor, A. O.
Oudard, S.
Ozguroglu, M.
Hansen, S.
Machiels, J. H.
Shen, L.
De Bono, J. S.
机构：
[1] Tulane Sch Med, New Orleans, LA USA
[2] George Pompidou European Hosp, Paris, France
[3] Istanbul Univ, Cerrahpasa Med Fac, Dept Med Oncol, Istanbul, Turkey
[4] Odense Univ Hosp, DK-5000 Odense, Denmark
[5] Catholic Univ Louvain, Ctr Canc, Clin Univ St Luc, B-1200 Brussels, Belgium
[6] Sanofi Aventis, Malvern, PA USA
[7] Inst Canc Res, Sutton, Surrey, England
[8] Royal Marsden Hosp, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4525
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4525
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC)
    Bracarda, Sergio
    Di Lorenzo, Giuseppe
    Gasparro, Donatello
    Marchetti, Paolo
    Boccardo, Francesco
    Martoni, Andrea
    Carteni, Giacomo
    Fornarini, Giuseppe
    Baldazzi, Valentina
    Dogliotti, Luigi
    Messina, Caterina
    Sisani, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [32] REGIONAL ANALYSIS OF A COHORT COMPASSIONATE-USE PROGRAM AND EARLY ACCESS PROGRAM WITH CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL
    Malik, Z.
    di Lorenzo, G.
    Bracarda, S.
    Ardavanis, A.
    Basaran, M.
    Parente, P.
    de Schultz, W.
    Saad, F.
    van Oort, I.
    Gerritsen, W. R.
    Aparicio, L. M. Anton
    Matus, G.
    Hitier, S.
    Heidenreich, A.
    Bahl, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 37 - 37
  • [33] A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).
    De Bono, J. S.
    Oudard, S.
    Ozguroglu, M.
    Hansen, S.
    Machiels, J. H.
    Shen, L.
    Sartor, A. O.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone plus prednisone
    Dubinsky, Samuel
    Thawer, Alia
    McLeod, Anne G.
    McFarlane, Thomas R. J.
    Emmenegger, Urban
    SUPPORTIVE CARE IN CANCER, 2019, 27 (09) : 3209 - 3217
  • [35] Clinical activity of abiraterone plus prednisone in docetaxel-naive and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
    Lin, Guo-Wen
    Li, Gao-Xiang
    Dai, Bo
    Ye, Ding-Wei
    Kong, Yun-Yi
    Wang, Yue
    Shen, Yi-Jun
    ASIAN JOURNAL OF ANDROLOGY, 2019, 21 (02) : 131 - +
  • [36] Erratum to: Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
    Carlo Buonerba
    Piera Federico
    Carmine D’Aniello
    Pasquale Rescigno
    Carla Cavaliere
    Livio Puglia
    Matteo Ferro
    Vincenzo Altieri
    Sisto Perdonà
    Sabino De Placido
    Giuseppe Di Lorenzo
    Cancer Chemotherapy and Pharmacology, 2011, 67 (6) : 1463 - 1463
  • [37] Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance
    Barqawi, Yazan K.
    Borrego, Matthew E.
    Roberts, Melissa H.
    Abraham, Ivo
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (11) : 1202 - 1209
  • [38] Association of Rash With Outcomes in a Randomized Phase II Trial Evaluating Cetuximab in Combination With Mitoxantrone Plus Prednisone After Docetaxel for Metastatic Castration-resistant Prostate Cancer
    Fleming, Mark T.
    Sonpavde, Guru
    Kolodziej, Michael
    Awasthi, Sanjay
    Hutson, Thomas E.
    Martincic, Danko
    Rastogi, Ashutosh
    Rousey, Steven R.
    Weinstein, Ralph E.
    Galsky, Matthew D.
    Berry, William R.
    Wang, Yunfei
    Boehm, Kristi A.
    Asmar, Lina
    Rauch, Mary A.
    Beer, Tomasz M.
    CLINICAL GENITOURINARY CANCER, 2012, 10 (01) : 6 - 14
  • [39] Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
    Zhenyu Yang
    Yuchao Ni
    Diwei Zhao
    Yijun Zhang
    Jun Wang
    Lijuan Jiang
    Dong Chen
    Zhiming Wu
    Yanjun Wang
    Liru He
    Yanxia Shi
    Fangjian Zhou
    Hao Zeng
    Yonghong Li
    BMC Cancer, 21
  • [40] Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
    Yang, Zhenyu
    Ni, Yuchao
    Zhao, Diwei
    Zhang, Yijun
    Wang, Jun
    Jiang, Lijuan
    Chen, Dong
    Wu, Zhiming
    Wang, Yanjun
    He, Liru
    Shi, Yanxia
    Zhou, Fangjian
    Zeng, Hao
    Li, Yonghong
    BMC CANCER, 2021, 21 (01)
12345